Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib probably leads to higher overall survival (absolute effect size estimates based on survival… compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (moderate certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
It is very uncertain whether sunitinib changes overall survival(absolute effect size estimates based on survival… compared with atezolizumab + bevacizumab (targeted agent versus immunotherapy +… (very low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Temsirolimus probably leads to lower overall survival survival (absolute effect size estimates based on… compared with IFN‐α (targeted agent versus classic immunotherapy) (moderate certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
It is very uncertain whether sunitinib changes overall survival (absolute effect size estimates based on survival… compared with atezolizumab (targeted therapy versus immunotherapy) (very low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Bevacizumab + IFN may leads to lower overall survival (absolute effect size estimates based on survival… compared with IFN (+ placebo) (targeted agent + classic immunotherapy versus… (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Temsirolimus + IFN‐α showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with IFN‐α (targeted agent + classic immunotherapy versus classic… (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Temsirolimus + bevacizumab showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (moderate certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether everolimus + bevacizumab changes overall survival (absolute effect size estimates based on survival… compared with IFN α‐2a + bevacizumab (targeted agent + targeted agent versus… (very low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
Sunitinib leads to higher overall survival (absolute effect size estimates based on survival… compared with nivolumab + ipilimumab (targeted agent versus combinations of… (high certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sorafenib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with pazopanib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with everolimus (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether sorafenib changes overall survival (absolute effect size estimates based on survival… compared with sunitinib (targeted agent versus targeted agent) (very low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Pazopanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with sunitinib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
Pazopanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with placebo (targeted agent versus placebo) (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes overall survival (absolute effect size estimates based on survival… compared with best supportive care alone (very low certainty).
1 finding from 1 review